The growing prevalence of infectious diseases, increasing antimicrobial resistance (AMR), and the rising demand for rapid diagnostic solutions are the key drivers of growth in the global clinical ...

Bio-Rad Laboratories ( (BIO) ) has shared an announcement.

Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc.

BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.

If you are wondering whether Bio-Rad Laboratories is starting to look attractively priced after a rough few years, this breakdown will help you put the current share price in context. The stock closed ...

In February 2026, Bio-Rad Laboratories reported fourth-quarter 2025 sales of US$693.2 million and net income of US$720 million, marking a return to profitability after a prior-year loss, alongside ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 Earnings Call Transcript February 12, 2026 Bio-Rad Laboratories, Inc. misses on earnings expectations. Reported EPS is $2.51 EPS, expectations were $2.57.

Good day, everyone, and welcome to the Bio-Rad Fourth Quarter and Full Year 2025 Results Conference Call. At this time, I would like to hand things over to Mr. Edward Chung. Please go ahead, sir. Good ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago. These ...

During the quarter, Bio-Rad recognized a substantial change in the fair market value of its investment in Sartorius AG, contributing to a GAAP net income of $720.0 million, or $26.65 per diluted share ...

The earnings results for Bio-Rad Laboratories (NYSE: BIO) for Q4 were made public on Thursday, February 12, 2026 at 04:15 PM.